Drugs / TollB-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06103773 | Sep 2023 → Jun 2024 | rheumatoid arthritis | Toll Biotech Co. Ltd. (Beijing) | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07408024 | Sep 2025 → Dec 2026 expected | rheumatoid arthritis | Toll Biotech Co. Ltd. (Beijing) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TollB-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06103773 ↗ |
| Modality | Small molecule | “new oral chemical drug” NCT07408024 ↗ |
| Route | Oral | “TollB-001 administered orally” NCT06103773 ↗ |